Search results
19 sie 2022 · The World Health Organization (WHO) has published its first guideline for Ebola virus disease therapeutics, with new strong recommendations for the use of two monoclonal antibodies. WHO calls on the global community to increase access to these lifesaving medicines.
- Ebola Virus Disease
WHO has made strong recommendations for the use of two...
- Therapeutics for Ebola virus disease
This first version of the Clinical management for EVD living...
- Ebola Virus Disease
According to the latest research, GP-specific antibodies are the most efficient post-exposure treatments for EVD. Ansuvimab-zykl, i.e., mAb114 (Ebanga™), is a recent FDA-approved human immunoglobulin monoclonal antibody targeting EBOV GP.
15 paź 2020 · October 14, 2020. Today, the U.S. Food and Drug Administration approved Inmazeb (atoltivimab, maftivimab, and odesivimab-ebgn), a mixture of three monoclonal antibodies, as the first...
WHO has made strong recommendations for the use of two monoclonal antibody treatments in treating Ebola: mAb114 (Ansuvimab; Ebanga) and REGN-EB3 (Inmazeb). The average Ebola case fatality rate is around 50%.
19 sty 2023 · Three years since proving effective for Ebola virus disease in a clinical trial, two breakthrough treatments are registered and stockpiled in the USA but still not registered and generally available in the countries most affected by this deadly infection of epidemic potential.
19 sie 2022 · The recommendation follows review and analysis of clinical trials for the monoclonal antibodies mAb114 (known as Ansuvimab or Ebanga) and REGN-EB3 (Inmazeb), which have...
19 sie 2022 · This first version of the Clinical management for EVD living guidance contains four new recommendations regarding use of therapeutics for EVD, this includes two strong recommendations for the use of monoclonal antibody therapies.
